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Intermittent preventive therapy for malaria:





Recent publications put a serious warning regarding the inefficacy of sulphadoxine-pyrimethamine (SP) for the
intermittent preventive treatment of malaria in young children (IPTi). Recommendations for other therapies are
being made. By using a different and better sulphonamide (sulphamethoxypyrazine), it is possible to manufacture
fixed dose combination pills with artesunate and pyrimethamine. This combination permits a full therapy over
24 hours (dosing interval being 12 hours). It is recommended that this combination should be tested in future field
studies of IPTi.
Background
Intermitted preventive therapy (IPT) is the administra-
tion of a full course of an anti-malarial drug at specified
time points in pregnant women and children, whether
parasites are present or not. It is expected that, by doing
so, the incidence of clinical malaria will be reduced in
the two patient groups. In pregnant women, the out-
comes are the neonatal weight and the presence of pla-
cental malaria and maternal anemia. The idea behind
the intermittent use of an anti-malarial drug is to lower
the risks for spreading resistance and prevent the
impairment of the development of natural immunity in
children [1]. Currently the intermittent preventive treat-
ment for malaria in infants (IPTi), children (IPTc) and
pregnant women (IPTp) is performed with a sulphona-
mide (sulphadoxine) in combination with pyrimetha-
mine, a combination which is no longer recommended
for malaria treatment [2]. The use for IPTi is currently
controversial as inconsistent data has been collected in
different efficacy studies regarding the degree of protec-
tion against malaria, the period of protective benefit and
the real positive effect on anaemia, hospital admission
and mortality. The lower efficacy due to growing resis-
tance to sulphadoxine-pyrimethamine and the high
incidence of serious adverse effects in treated children
are also issues of concern [3,4]. For instance, in a recent
paper of Gosling et al comparing efficacy of SP, chlor-
proguanil-dapsone and mefloquine for preventing clini-
cal malaria in infant, the first two regimens had no
protective effect at all, and mefloquine had a protective
effect of 38.1% [5]. Therefore, new drugs or drug combi-
nations are needed for IPTi. Cairns et al suggested that
“The ideal regimen for IPTi and IPT in older children
would be a fixed formulation of two long-acting anti-
malarials with similar pharmacokinetic profiles that
c o u l db eg i v e na sas i n g l ed o s ea n db ep e r f e c t l ys a f e ”
[6]. In a recent editorial, McGready suggested that pre-
ventive intermittent therapy in children below one year
of age is probably not worth it since children are rela-
tively protected from malaria in the first few months of
their life [7]. She concluded that for IPTi, SP is the
w r o n gd r u gi nt h ew r o n gd o s ea tt h ew r o n gt i m e .T h i s
opinion contrasts with a meta-analysis involving six stu-
dies, published by Aponte et al where it was concluded
that intermittent treatment with SP prevented malaria
for about one month after each dose [8]. The point of
view of McGready is interesting: following the loss of SP
as a treatment regimen for symptomatic malaria,
the question is whether the days of SP and similar drugs
as preventive monotherapy are over? Probably yes. Correspondence: fhjansen@actionafrique.com
ACT-ion Afrique, Brussels, Belgium
Jansen Malaria Journal 2011, 10:70
http://www.malariajournal.com/content/10/1/70
© 2011 Jansen; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.The arguments to conclude this will be developed in the
following paragraphs.
Sulphonamides for malaria
The use of sulphonamide in combination with pyri-
methamine for the treatment of malaria goes back to
the early seventies when Hoffman-La-Roche introduced
the drug Fansidar
®. It was recommended to use this
combination as follows: three tablets containing 500 mg
sulphadoxine and 25 mg pyrimethamine, as a single
dose. Nearly at the same time a competitive drug was
launched by Farmitalia under the brand name Metakel-
fin
® containing as sulphonamide sulphamethoxypyrazine
(SM), but it was introduced in a limited number of
countries only. Both SP and sulphamethoxypyrazine-pyr-
imethamine (SMP) have been used in Africa for many
years and were only recently stopped being recom-
mended for the curative treatment of malaria in some
African countries in favour of artemisinin-based combi-
nation therapy (ACT). In the past, the combination with
SP or SMP worked well, was cheap and well-accepted in
virtually all areas where malaria is abundant.
The combination SP was selected by some for inter-
mittent therapy in infant, children and in pregnant
women. But why SP was preferred over SMP is not
clear. Although both sulphonamides are relatively safe,
it is known that fewer side effects have been seen with
sulphamethoxypyrazine than with sulphadoxine [2]. In
fact, SMP is still considered by many as the “best sul-
phonamide-pyrimethamine” combination. In fact, long
ago the drug was strongly recommended by WHO and
used in a large malaria eradication programme in the
hyperendemic malarial area of Garki, Nigeria [9], and
not a single side effect was reported in clinical efficacy
trials.
SP and SMP act by inhibiting the folic acid biosynth-
esis of the parasite (but also of bacteria) at two levels.
First, the sulphonamide acts as a competitive inhibitor
with p-amino benzoic acid in the first part of the synth-
esis of folic acid. At a later stage, pyrimethamine inter-
feres with the dihydrofolate reductase enzyme necessary
to reduce the intermediate compound dihydrofolate into
folic acid [10]. Unfortunately, parasites, including Plas-
modium falciparum, can mutate around its action and
SP resistance can be very high in certain areas like
Ghana and Rwanda, where 35 and 50% resistance are
reported, respectively [11,12]. Mutations can be mani-
fold and are particularly directed against the reductase
enzyme that is the target for pyrimethamine. Mutations
against the synthase enzyme are more unlikely since the
sulphonamide does not interfere with the enzyme sys-
tem involved. From a practical point of view, this means
that SP can become useless in case they are used in chil-
dren suffering from an infection caused by resistant
parasites, as it was probably the case in the patients stu-
died by Gosling et al [5].
The use of combination therapies including artesunate
or artemether could also be theoretically possible for
IPT and represent a valid alternative to sulfonamide
alone. Cissé et al published in 2006 their positive experi-
ence when using a single dose of artesunate combined
with one dose of SP leading to a clear-cut prevention of
malaria over a 13-week follow-up period [13]. However,
using only one tablet of artesunate and one dose of SP
is dangerous and may lead to the development of resis-
tance since this combination is not capable of appropri-
ately reducing the parasite load. If one would rather give
a full treatment, making fixed dose preparations of arte-
sunate with SP is not feasible since artesunate should be
given in three doses over three days (48 h) and the SP
part is administered as a single high dose (1,500 mg).
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comparable therapeutic effect as 1,500 mg of SP. In fact
despite the fact that both sulphonamides are considered
to be long acting, SP has a longer elimination half life
(about 200 h but variable) and a very high binding to
plasma proteins (between 95 and 99%). In contrast the
elimination half life of SMP is 65-85 hours and plasma
protein binding is only 65% [14]. Since for sulphona-
mide therapy only the non-protein-bound part of the
drug (the so called free fraction which distributes in all
body compartments) is active against bacteria and para-
sites, a much smaller dose of SMP can be given when
compared to SP. This also means that administering a
larger dose of SMP (like the dose given for SP) results
in a much longer duration of action than that of a com-
parable dose of SP.
Conversely to SP, it is possible to make a true fixed
dose preparation of SMP and artesunate. This was done
by the Belgian company Dafra Pharma which introduced
this as a malaria therapeutic agent under the brand
name Co-arinate
®. Each pill for adults contains 200 mg
artesunate, 500 mg sulphamethoxypyrazine and 25 mg
pyrimethamine. The tablets for children contain half
that dose and for infants the tablets can easily be broken
so that the half unit contains only 50 mg artesunate
with 125 mg sulphonamide and 6.25 mg pyrimethamine.
Several studies involving several thousands of patients
support the clinical efficacy against that combination
[12,15-18]. The incidence of side effects is very low and
adequate clinical and parasitological cure rates (APCR)
PCR corrected at day 28 reaches up to 99% level. Inter-
estingly, the drug is also highly efficacious in areas with
pronounced SP resistance like in Rwanda [9]. The full
curative dosing can be done over 24 h (dose interval
12h) or 48 h (dose interval 24 h).
In the author’s opinion, the use of a FDC with artesu-
nate should seriously be reconsidered for IPTi, and the
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Page 2 of 3combination As+SMP represents a good candidate drug
for such use. In fact, the drug is highly efficacious, it is
safe, simple to administer and its production cost is
very low.
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